{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T06:27:36Z","timestamp":1792218456838,"version":"4.4.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.ejca.2022.01.015","type":"journal-article","created":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T10:54:50Z","timestamp":1645440890000},"page":"48-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":47,"special_numbering":"C","title":["FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel \u2013 results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO"],"prefix":"10.1016","volume":"165","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7933-2507","authenticated-orcid":false,"given":"Sylvie","family":"Lorenzen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8544-9872","authenticated-orcid":false,"given":"Peter","family":"Thuss-Patience","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Pauligk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1338-419X","authenticated-orcid":false,"given":"Eray","family":"G\u00f6kkurt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7654-2442","authenticated-orcid":false,"given":"Thomas","family":"Ettrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Lordick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Stahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Reichardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"S\u00f6kler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7243-7373","authenticated-orcid":false,"given":"Daniel","family":"Pink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Probst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel","family":"Hinke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsten O.","family":"Goetze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salah E.","family":"Al-Batran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2022.01.015_bib1","first-page":"7","article-title":"Cancer statistics","volume":"50","author":"Greenlee","year":"2000","journal-title":"CA Cancer J Clin"},{"issue":"15","key":"10.1016\/j.ejca.2022.01.015_bib2","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.ejca.2011.06.002","article-title":"Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)","volume":"47","author":"Thuss-Patience","year":"2011","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2022.01.015_bib3","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1470-2045(13)70549-7","article-title":"Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial","volume":"15","author":"Ford","year":"2014","journal-title":"Lancet Oncol"},{"issue":"13","key":"10.1016\/j.ejca.2022.01.015_bib4","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1200\/JCO.2011.39.4585","article-title":"Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone","volume":"30","author":"Kang","year":"2012","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.ejca.2022.01.015_bib5","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.1200\/JCO.2012.48.5805","article-title":"Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial","volume":"31","author":"Hironaka","year":"2013","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2022.01.015_bib6","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/jjco\/hyn078","article-title":"Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer","volume":"38","author":"Seo","year":"2008","journal-title":"Jpn J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ejca.2022.01.015_bib7","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"},{"issue":"10184","key":"10.1016\/j.ejca.2022.01.015_bib8","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.ejca.2022.01.015_bib9","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1200\/JCO.18.01138","article-title":"Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage III gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial","volume":"37","author":"Yoshida","year":"2019","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2022.01.015_bib10","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1093\/annonc\/mdw423","article-title":"Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial","volume":"27","author":"Yoon","year":"2016","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2022.01.015_bib11","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jamaoncol.2016.5580","article-title":"Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2-negative, MET-positive gastroesophageal adenocarcinoma: the METGastric randomized clinical trial","volume":"3","author":"Shah","year":"2017","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2022.01.015_bib12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for research and treatment of cancer, National cancer Institute of the United States, National cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2022.01.015_bib13","series-title":"Cancer Therapy Evaluation Program: common terminology criteria for adverse events v","year":"2009"},{"key":"10.1016\/j.ejca.2022.01.015_bib14","series-title":"Clinical trials in cancer","first-page":"30","author":"Girling HP","year":"2003"},{"issue":"4","key":"10.1016\/j.ejca.2022.01.015_bib15","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10120-011-0135-0","article-title":"Efficacy of weekly paclitaxel in patients with advanced gastric cancer refractory to docetaxel-based chemotherapy","volume":"15","author":"Ando","year":"2012","journal-title":"Gastric Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2022.01.015_bib16","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1097\/00001813-200009000-00003","article-title":"Single-agent docetaxel in metastatic breast cancer patients pre-treated with anthracyclines and paclitaxel: partial cross-resistance between paclitaxel and docetaxel","volume":"11","author":"Lin","year":"2000","journal-title":"Anticancer Drugs"},{"issue":"6","key":"10.1016\/j.ejca.2022.01.015_bib17","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1159\/000217264","article-title":"Paclitaxel, estramustine and carboplatin combination chemotherapy after initial docetaxel-based chemotherapy in castration-resistant prostate cancer","volume":"76","author":"Sella","year":"2009","journal-title":"Oncology"},{"issue":"10","key":"10.1016\/j.ejca.2022.01.015_bib18","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1200\/JCO.1998.16.10.3362","article-title":"A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer","volume":"16","author":"Valero","year":"1998","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2022.01.015_bib19","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00280-018-3678-5","article-title":"Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with\/without platinum and taxane","volume":"82","author":"Satake","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"10.1016\/j.ejca.2022.01.015_bib20","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1634\/theoncologist.2018-0602","article-title":"Initial report of second-line FOLFIRI in combination with ramucirumab in advanced gastroesophageal adenocarcinomas: a multi-institutional retrospective analysis","volume":"24","author":"Klempner","year":"2019","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.ejca.2022.01.015_bib21","doi-asserted-by":"crossref","first-page":"366","DOI":"10.21037\/jgo.2020.03.10","article-title":"Ramucirumab plus paclitaxel or FOLFIRI in platinum-refractory advanced or metastatic gastric or gastroesophageal junction adenocarcinoma-experience at two centres","volume":"11","author":"Vogl","year":"2020","journal-title":"J Gastrointest Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922000363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922000363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:35:11Z","timestamp":1760733311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922000363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":21,"alternative-id":["S0959804922000363"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.01.015","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel \u2013 results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}